Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium Selenite with Palliative Radiation in Metastatic Cancer
NCT02184533Phase 1Completed
- Sponsor
- Stanford University
- Start
- Jul 2014
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sodium selenite in metastatic cancer, sponsored by Stanford University. Primary endpoints: Maximum Tolerated Dose at 3 weeks and Safety and tolerability of the combination up to 2 years. Started Jul 2014; status: completed.
02
Drugs
sodium selenite
03
Conditions
metastatic cancer
Beyond the preview
Go deeper on NCT02184533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02184533.